Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v2.4.0.6
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Revenues:    
Royalties $ 3,060 $ 1,993
Material sales 667 1,019
Collaborative research and development and other revenues 1,909 884
Total revenues 5,636 3,896
Operating costs and expenses:    
Cost of sales 155 525
Research and development 2,817 1,986
General and administrative 3,503 3,445
Lease exit and termination costs (74) (151)
Total operating costs and expenses 6,401 5,805
Accretion of deferred gain on sale leaseback   426
Loss from operations (765) (1,483)
Other income (expense):    
Interest income 17 37
Interest expense (792) (423)
Decrease (increase) in contingent liabilities 513 (2,288)
Other, net 254 48
Total other income (expense), net (8) (2,626)
Loss before income taxes (773) (4,109)
Income tax benefit (expense) 35 13,730
Income (loss) from continuing operations (738) 9,621
Discontinued operations:    
Income tax benefit (expense) on discontinued operations (177)  
Discontinued operations 1,871 4
Net income 1,133 9,625
Basic and diluted per share amounts:    
Income (Loss) from continuing operations $ (0.04) $ 0.49
Discontinued operations $ 0.10  
Net income $ 0.06 $ 0.49
Weighted average number of common shares-basic and diluted 19,709,078 19,623,249
AVINZA Product Line [Member]
   
Discontinued operations:    
Gain on sale of Product Line before income taxes 2,048  
Oncology Product Line [Member]
   
Discontinued operations:    
Gain on sale of Product Line before income taxes   $ 4